Author(s)

Jihad Haddad^1*, Fares H. Haddad², Rashad Nasser³, Abdel-Ellah Al-Shudifat¹, Firas Abbas Annabi⁴, Levent Sandalci⁵, Moawia Al-Kilani⁶

¹Prince Hamzah Hospital, Amman, Jordan.
²King Hussein Medical Center, Amman, Jordan.
³Italian Hospital, Amman, Jordan.
⁴Islamic Hospital, Amman, Jordan.
⁵Novo Nordisk Business Area Near East, Istanbul, Turkey.
⁶Jabal Al Zayton Hospital, Zarqa, Jordan.

Objective: To analyse the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in a Jordanian subgroup of the 24-week, non-interventional A1chieve study. Methods: A total of 509 Jordanian patients with type 2 diabetes (392 insulin-naive and 117 insulin-experienced) starting BIAsp30, alone or in combination with oral glucose-lowering drugs, were included. Safety and effectiveness outcomes were analysed over 24 weeks. Results: Patients had a mean age of 55.8 years, body mass index of 28.8 kg/m² and diabetes duration of 9.4 years at baseline. Two serious adverse drug reactions of hypoglycaemia were reported. The proportion of patients who reported major hypoglycaemic events decreased (2.4% at baseline vs. 0.2% at Week 24, p = 0.0039). The proportion of patients reporting overall hypoglycaemia increased marginally (6.3% at baseline vs. 9.9% at Week 24, p = 0.0378), primarily attributed to a rise in minor and nocturnal hypoglycaemia reported in insulin-naive patients. From baseline to Week 24, the mean ± SD glycated haemoglobin A1c level decreased from 9.8% ± 1.4% to 7.4% ± 0.9% (p < 0.001). Significant reductions after 24 weeks were also noted in the mean fasting plasma glucose, postprandial plasma glucose, lipids, systolic blood pressure and quality of life (all p < 0.001), while the mean body weight increased by 1.8 ± 6.5 kg (p < 0.001). Conclusion: Overall, BIAsp 30 therapy was well-tolerated and resulted in improved glycaemic control in this Jordanian subgroup over 24 weeks.

Biphasic Insulin Aspart 30, Jordan, Type 2 Diabetes, A₁chieve, Clinical Practice

Haddad, J. , Haddad, F. , Nasser, R. , Al-Shudifat, A. , Annabi, F. , Sandalci, L. and Al-Kilani, M. (2014) Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients with Type 2 Diabetes: Results from the Jordanian Subgroup of the A₁chieve Study. Journal of Diabetes Mellitus, 4, 379-387. doi: 10.4236/jdm.2014.44051.